Comparative Pharmacology
Head-to-head clinical analysis: EXKIVITY versus XALKORI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXKIVITY versus XALKORI.
EXKIVITY vs XALKORI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible tyrosine kinase inhibitor that selectively targets epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, and specifically inhibits EGFR T790M and C797S resistance mutations, with less activity against wild-type EGFR.
Selective tyrosine kinase inhibitor targeting ALK, ROS1, and MET, inhibiting downstream signaling pathways (PI3K/AKT, MAPK/ERK) leading to reduced tumor cell proliferation and survival.
150 mg orally once daily with or without food.
250 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 48 hours, supporting once-daily dosing for systemic exposure.
Terminal elimination half-life is approximately 72 hours (range 47-108 hours) in patients, supporting once-daily dosing.
Primarily hepatic metabolism with biliary excretion; 91% of total recovered in feces (30% as unchanged drug), <1% in urine.
Primarily hepatic metabolism, with 53% of the dose recovered in feces (mostly as metabolites) and 22% in urine (1.1% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor